New drug targets Hard-to-Treat cancers in early trial

NCT ID NCT06805825

First seen Nov 01, 2025 · Last updated May 04, 2026 · Updated 23 times

Summary

This early-stage trial tests a new drug, NN3201, designed to attack cancer cells that have a specific marker called c-Kit. The study includes people with advanced or spreading cancers like gastrointestinal stromal tumors (GIST), small-cell lung cancer, and others. The main goal is to check the drug's safety and find the best dose, with 67 participants expected.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOID CYSTIC CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Case Comprehensive Cancer Center

    RECRUITING

    Cleveland, Ohio, 44106, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • NEXT Virginia

    ACTIVE_NOT_RECRUITING

    Fairfax, Virginia, 22031, United States

  • Oregon Health & Science University

    RECRUITING

    Portland, Oregon, 97239, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The University of Texas MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Michigan Hospitals

    RECRUITING

    Ann Arbor, Michigan, 48109-9001, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.